Effect of Limosilactobacillus Reuteri DSM 17648 in Healthy Adults Reporting Upper Gastrointestinal Discomfort
← catalyst calendarSponsored by Novozymes A/S (industry) · NSIS-B.CO — their whole pipeline →. With Citruslabs.
Phase
Not applicable
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
324actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-08 | actual | When the study began enrolling |
| Primary completion | 2026-05-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-27 | actual | The whole study's end, after follow-up |
| First posted | 2025-09-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Participants
- Upper Gastrointestinal Discomfort
Interventions
- Dietary supplement: Limosilactobacillus reuteri DSM 17648 — also filed as Pylopass, PyloGuard
- Dietary supplement: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from Baseline in the total score of Frequency Scale for the Symptoms of GERD (FSSG) at 8 weeks
measured Baseline; 8 weeks
Permalink · NSIS-B.CO's whole pipeline · Catalyst calendar · Every registered study · What changed